BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy Trial
Portfolio Pulse from Vandana Singh
BioXcel Therapeutics announced overall survival data from its Phase 2 trial of BXCL701 in combination with Merck's Keytruda in patients with metastatic castration-resistant prostate cancer. The company reported a RECIST partial response rate of 28% with a median duration of response of 19 months. BioXcel is also evaluating strategic options for its subsidiary OnkosXcel Therapeutics, including potential financing, strategic partnership, or M&A. BTAI shares are down 6.78% at $4.51.
November 08, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioXcel Therapeutics announced positive survival data from its Phase 2 trial of BXCL701, but its shares are down 6.78%. The company is also considering strategic options for its subsidiary OnkosXcel Therapeutics.
The positive survival data from the Phase 2 trial of BXCL701 could potentially increase investor confidence in the company's product pipeline. However, the company's shares are down, indicating a negative market reaction. The company's consideration of strategic options for its subsidiary OnkosXcel Therapeutics could also impact its financial stability and future growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Merck's Keytruda was used in combination with BioXcel's BXCL701 in a Phase 2 trial for prostate cancer, showing positive survival data.
The use of Merck's Keytruda in combination with BioXcel's BXCL701 in a Phase 2 trial and the positive survival data could potentially increase investor confidence in Merck's product and its potential for future collaborations. However, the impact on Merck's stock price may be limited as it is a large pharmaceutical company with a diverse product portfolio.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50